Breaking News: AUM Biosciences acquires Small Molecule ETC-206 – A Novel, Highly Selective Anti-Cancer Drug

AUM Biosciences is delighted to announce our first acquisition of Singapore’s home-grown small molecule ETC-206 from A*STAR’s Experimental Therapeutics Centre (ETC). The first in our pipeline, this novel, highly selective anti-cancer drug, continues to pave the way for our “Asia to Global” approach by accelerating the development of innovative and affordable medicines. ETC-206’s licensing by AUM puts both Singapore and the company at the forefront of emerging oncology trends. The drug’s ability to isolate and target only cancerous cells promises a breakthrough opportunity globally. Read more below.